IMMIX BIOPHARMA, INC. Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- IMMIX BIOPHARMA, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $11.16K, a 91.62% increase year-over-year.
- IMMIX BIOPHARMA, INC. stock issued during period, value, stock options exercised for the quarter ending 2026-03-31 was $33.53K.
- IMMIX BIOPHARMA, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-09-30 was $516.00.
- IMMIX BIOPHARMA, INC. stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $5.82K.
- IMMIX BIOPHARMA, INC. stock issued during period, value, stock options exercised for fiscal 2025 was $6.34K, a 154.80% increase from fiscal 2024.
- IMMIX BIOPHARMA, INC. stock issued during period, value, stock options exercised for fiscal 2024 was $2.49K, a 4.93% decline from fiscal 2023.
- IMMIX BIOPHARMA, INC. stock issued during period, value, stock options exercised for fiscal 2023 was $2.62K.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $11.16K 10-Q · filed 2026-08-07 | |
| 2026-03-31 | $33.53K 10-Q · filed 2026-08-07 | |
| 2025-12-31 | $6.34K 10-K/A · filed 2026-03-27 | |
| 2025-09-30 | $516.00 10-Q · filed 2025-11-07 | |
| 2025-06-30 | $5.82K 10-Q · filed 2026-08-07 | |
| 2024-12-31 | $2.49K 10-K/A · filed 2026-03-27 | |
| 2024-03-31 | $2.49K 10-Q · filed 2025-11-07 | |
| 2023-12-31 | $2.62K 10-K · filed 2025-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |